|
Multi Sciences (Lianke) Biotech Co Ltd
enzyme linked immunosorbent assay elisa ![]() Enzyme Linked Immunosorbent Assay Elisa, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Human+Serum+Amyloid+A1+%2FSAA1+ELISA+Kit/pmc13181087-322-8-12 Average 91 stars, based on 1 article reviews
enzyme linked immunosorbent assay elisa - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
TargetMol
recombinant human saa1 ![]() Recombinant Human Saa1, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/SAA1+Protein%2C+Human%2C+Recombinant/pmc13693122-258-30-37 Average 94 stars, based on 1 article reviews
recombinant human saa1 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
RayBiotech inc
human saa elisa kit ![]() Human Saa Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Human+SAA+ELISA/pm26058824-70-1-9 Average 94 stars, based on 1 article reviews
human saa elisa kit - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
OriGene
recombinant human saa1 ![]() Recombinant Human Saa1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Serum+Amyloid+A+(SAA1)+(NM_199161)+Human+Recombinant+Protein/pmc06179936-96-0-12 Average 90 stars, based on 1 article reviews
recombinant human saa1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
OriGene
eukarytoic recombinant human saa1 1 ![]() Eukarytoic Recombinant Human Saa1 1, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Serum+Amyloid+A+(SAA1)+(NM_000331)+Human+Recombinant+Protein/pmc09935590-9-0-5 Average 91 stars, based on 1 article reviews
eukarytoic recombinant human saa1 1 - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
Creative BioMart
human saa1 ![]() Human Saa1, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Recombinant+Human+SAA1/pmc12520672-202-10-13 Average 93 stars, based on 1 article reviews
human saa1 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
ABclonal Biotechnology
recombinant human saa1 ![]() Recombinant Human Saa1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Recombinant+Human+SAA1+Protein/pmc13181338-47-0-3 Average 94 stars, based on 1 article reviews
recombinant human saa1 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
OriGene
human saa1 ![]() Human Saa1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Serum+Amyloid+A+(SAA1)+(NM_199161)+Human+Tagged+ORF+Clone/pmc09291269-593-5-8 Average 90 stars, based on 1 article reviews
human saa1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
MedChemExpress
recombinant protein saa1 ![]() Recombinant Protein Saa1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/SAA1%2C+Human/pmc12486657-136-1-10 Average 93 stars, based on 1 article reviews
recombinant protein saa1 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Sino Biological
md2 cat no hg11298 nf cdna ![]() Md2 Cat No Hg11298 Nf Cdna, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Human+SAA1+Gene+ORF+cDNA+clone+expression+plasmid%2C+N-Flag+tag/pm40012323-88-17-24 Average 93 stars, based on 1 article reviews
md2 cat no hg11298 nf cdna - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
OriGene
recombinant saa1 ![]() Recombinant Saa1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Serum+Amyloid+A+(SAA1)+(NM_000331)+Human+Recombinant+Protein/pmc07753654-63-42-48 Average 90 stars, based on 1 article reviews
recombinant saa1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
OriGene
human recombinant saa1 protein ![]() Human Recombinant Saa1 Protein, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+saa1/Serum+Amyloid+A+(SAA1)+(NM_000331)+Human+Recombinant+Protein/pmc12989110-39-0-5 Average 94 stars, based on 1 article reviews
human recombinant saa1 protein - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Nature Communications
Article Title: CD8 + T cell loss induces autoinflammation in inborn errors of cell death
doi: 10.1038/s41467-026-70317-2
Figure Lengend Snippet: a , b Schematic diagram showing serum cytokine microarray analysis of continuous P2’s serum samples before (PS1 and PS2) or after (PS3, flare; PS4 and PS5, non-flare) the onset of recurrent fever ( a ). PCA analysis of sample variance determined by semi-quantitative 174 cytokines antibody array on serum samples of C1-C3 from three unaffected controls and PS1-PS5 from P2 ( b ). c–e The integrated relative MFI plots of P2’s serum cytokine levels. 26 cytokines peaked in PS3 were enrich in group 1 (left), 24 cytokines higher than control were enriched in group 2 (right) ( c ). The relative MFI was calculated by normalizing the average MFI of the unaffected controls ( n = 3) to 0, and setting the largest MFI to 1 or the smallest MFI to −1 across 5 samples from P2. Boxplots exhibiting expression scores of cytokines of group 1 ( d ) and group 2 ( e ) in indicated cell with Seurat AddModuleScore function. The cell number of each subtype (listed in the “Methods” section), was employed for p value calculations. Boxes show the median (center line), 25th and 75th percentiles (upper and lower hinges), and whiskers extend to 1.5× the interquartile range, representing the maximum and minimum values. f Average expression values (arcsinh transformed) of cl. Casp-3 across identified peripheral immune cell lineages in PBMCs freshly isolated from four unaffected controls (C) and two patients (P, 1 sample from P1 and 2 samples from P2) by mass cytometry by time-of-flight (CyTOF) analysis. g–j Representative contour plots of cl. Casp-3 ( g , h ) and histograms of total RIPK1, pRIPK1(S166) levels ( i , j ) in CD4 + T and CD8 + T cells in freshly isolated PBMCs from unaffected controls (for cl. Casp-3, n = 12; for pRIPK1(S166), n = 10) and patients ( n = 4 for P1 and P2) (left). Summary histograms of cl. Casp-3 and pRIPK1(S166) (right) were shown. k Representative histogram and statistical analysis of surface CD69 expression on CD3 + T cells from unaffected controls ( n = 7) and two patients ( n = 3 for P1 and P2). l Serum IFNγ, sCD25, sCD95 and CD95L of unaffected controls (for IFNγ, n = 9; for sCD25, n = 15; for sCD95 and CD95L, n = 10), two patients (for IFNγ, P1, n = 5, P2 = 6; for sCD25, P1, n = 5, P2, n = 4; for sCD95, P1 and P2, n = 7; for CD95L, P1 = 7; P2 = 8) and their parents (for IFNγ and sCD25, n = 7; for sCD95 and CD95L, n = 6) as well as two CRIA syndrome patients ( n = 6) determined by ELISA. T denotes 10 ng ml -1 TNF; S denotes 250 nM SM164; Z denotes 25 μM z-VAD-fmk. All histogram graphs show mean ± SD. P values were determined by two-tailed unpaired t-test. Data in g–k were pooled from two independent experiments.
Article Snippet: Human or mouse serum cytokines were measured by
Techniques: Microarray, Ab Array, Control, Expressing, Transformation Assay, Isolation, Mass Cytometry, Enzyme-linked Immunosorbent Assay, Two Tailed Test
Journal: Nature Communications
Article Title: CD8 + T cell loss induces autoinflammation in inborn errors of cell death
doi: 10.1038/s41467-026-70317-2
Figure Lengend Snippet: a Schematic diagram of T cell-MDM co-culture system. b , c qRT-PCR analysis of TNF, IL1B and IL6 mRNA levels in GM-CSF-activated monocytes derived macrophages (MDMs) co-cultured with or without T cells for 6 h. GM-CSF-activated MDMs generated from ( b , left) unaffected control 1 (C1) or ( b , right) unaffected control 3 (C3) or P1 ( c ) were co-cultured with donor-matched T cells as well as T cells from other unaffected controls (C2 and C4) or patients as indicated. d Dot plot of IFNG, TNF in cell subtypes found in scRNA-seq of PBMCs from three unaffected controls and two patients. e Representative histograms and statistical analysis of TNF and IFNγ expression in CD8 + T cells in PBMCs isolated from unaffected controls ( n = 6) and patients ( n = 3 from P1 and P2) treated with 10 ng ml -1 TNF (T) with or without 250 nM SM-164 (S), 25 μM z-VAD-fmk (Z) for 24 h. f , T cells isolated from P2 were co-cultured with MDMs generated from unaffected control in the presence of 10 μg ml -1 adalimumab, 10 μg ml -1 emapalumab alone or in combination for 6 h. TNF, IL1B and IL6 mRNA levels of MDMs were analyzed by qRT-PCR. g Experimental timeline for generation of lineage negative bone marrow cells (Lin - BMs)-transplanted mice with conditional overexpression of human WT or mutated RIPK1 K377E or R390G in CD8 + T cell- or myeloid cell-specific lineage. h, i ELISA measurement of serum Tnf and Il6 levels in mice specifically overexpressing WT or mutated hRIPK1 in ( h ) CD8 + T cells (EV, n = 5; WT, K377E and R390G n = 7) or ( i ) myeloid cells (EV, n = 5; WT, K377E and R390G n = 6). All histogram graphs show mean ± SD. P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. Data in b , c , and f show the means ± SD of technical triplicates. The results shown in b were derived from two independent experiments using cells from different donors. The experiment in ( c , h , i , f ) is representative of two independent experiments. Data in e were pooled from two independent experiments.
Article Snippet: Human or mouse serum cytokines were measured by
Techniques: Co-Culture Assay, Quantitative RT-PCR, Derivative Assay, Cell Culture, Generated, Control, Expressing, Isolation, Over Expression, Enzyme-linked Immunosorbent Assay
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma
doi: 10.1186/s13046-026-03792-6
Figure Lengend Snippet: Osimertinib upregulates SAA1, which associates with poor clinical outcomes in LUAD. A Schematic of short-term osimertinib exposure (IC 50 , 48 h) in three EGFR-mutant LUAD cell lines (PC-9, HCC827, H1975). Venn diagram illustrates consistently dysregulated secreted-protein genes across the three cell lines. B RNA-seq analysis identifying six differentially expressed secreted-protein genes, with FPKM shown in each dot. C - D Western blot, and ELISA assay validation of SAA1 upregulation, demonstrating a dose-dependent increase in PC-9 and H1975 cells ( n = 3). E Relative cell viability assays confirming ≥ 20-fold resistance to osimertinib in established OR cell lines (PC-9 OR , H1975 OR ) ( n = 3). F - G qPCR and western blot results of SAA1 expression across DTPCs and long-term OR models ( n = 3). H Representative IHC staining of SAA1 in normal lung tissue, LUAD tumors before TKI treatment, and TKI-treated LUAD samples. Scale bar, 20 μm. I Quantification of SAA1 IHC H-scores in paired EGFR-mutant LUAD samples collected before and after neoadjuvant osimertinib treatment ( n = 5). J Western blot analysis of paired EGFR-mutant LUAD tumors before (TKI-naïve) and after osimertinib (TKI-residual) treatment ( n = 5). K Kaplan-Meier analysis of disease-free survival of adjuvant osimertinib-treated LUAD patients ( n = 40). Dunnett’s multiple comparison tests were applied for panels D and F ; two-way ANOVA test for panel E; Paired Student’s t-test for panel I; and log-rank test for panel K. Abbreviations: PR, parental; OR, osimertinib-resistant; DTPC, drug-tolerant persister cells; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry
Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and
Techniques: Mutagenesis, RNA Sequencing, Analysis, Western Blot, Enzyme-linked Immunosorbent Assay, Biomarker Discovery, Expressing, Immunohistochemistry, Tissue, Adjuvant, Comparison
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma
doi: 10.1186/s13046-026-03792-6
Figure Lengend Snippet: SAA1 is required for both drug tolerance and established osimertinib resistance. A - B Relative cell viability and proliferation assays with different generations of EGFR-TKI (10 nM) in parental EGFR-mutant LUAD cell lines transfected with two independent siRNAs targeting SAA1 in PC-9 and H1975 cells ( n = 3). C Western blot confirming the establishment of SAA1-OE and SAA1-KO OR cell models generated by lentiviral transduction. D - E Relative cell viability and proliferation assays (10 nM) with different generations of EGFR-TKI in SAA1-OE, SAA1-KO OR models, and SAA1-KO cells rescued with exogenous SAA1 (100 ng/ml) ( n = 3). F Quantification of DTPC formation efficiency in LUAD cells treated with PBS or exogenous SAA1 (100 ng/ml) ( n = 3). G - H In vivo assessment using a PC-9 OR CDX model established with cells transduced with either a negative control vector or SAA1-KO lentivirus. Mice received daily oral gavage of osimertinib (5 mg/kg) or saline for 9 consecutive days ( n = 6). Tumor growth curves ( G ) and representative final tumor specimens ( H ) are shown. Dunnett’s multiple comparison tests were used for panels B and E , and two-way ANOVA test was applied for panel G . Abbreviations: SAA1-OE, SAA1 overexpression; SAA1-KO, SAA1 knockout; OR, osimertinib-resistant; Osi, osimertinib; Gef, gefitinib; Afa, afatinib; TKI, tyrosine kinase inhibitor; DTPC, drug-tolerant persister cells
Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and
Techniques: Mutagenesis, Transfection, Western Blot, Generated, Transduction, In Vivo, Negative Control, Plasmid Preparation, Saline, Comparison, Over Expression, Knock-Out
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma
doi: 10.1186/s13046-026-03792-6
Figure Lengend Snippet: SAA1 activates the TLR4/NF-κB pathway to drive osimertinib resistance. A Heatmap showing the expression patterns of NF-κB-associated genes in PC-9 cells treated with exogenous SAA1 (100 ng/ml, 24 h) compared with PBS. B GSEA plot indicating enrichment of the NF-κB signaling pathway in SAA1-treated PC-9 cells. C - D Western blot analysis of whole-cell lysates ( C , assessing p65, p-p65, IκBα, and p-IκBα) and subcellular fractions ( D , assessing nuclear and cytoplasmic p65) in PC-9 OR and H1975 OR cells transfected with vector control, SAA1 overexpression, SAA1 knockout, or SAA1 knockout rescued with exogenous SAA1. E - F Western blot evaluating the effect of the NF-κB inhibitor BAY 11-7082 (5 µM) on SAA1-induced pathway activation in whole-cell lysates ( E ) and subcellular fractions ( F ). G - H Western blot evaluating the effect of the TLR4 inhibitor TAK-242 (10 µM) on SAA1-induced pathway activation in whole-cell lysates ( G ) and subcellular fractions ( H ). I - L Cell proliferation curves ( I , K ) and relative cell viability assays determining osimertinib IC50 ( J , L ) in PC-9 OR and H1975 OR cells treated with PBS or exogenous SAA1, in the presence or absence of BAY 11-7082 (5 µM) or TAK-242 (10 µM) ( n = 3). Two-way ANOVA tests were applied for panels I - L . Abbreviations: SAA1-OE, SAA1 overexpression; SAA1-KO, SAA1 knockout; OR, osimertinib-resistant; NF-κBi, NF-κB inhibitor; TLR4i, TLR4 inhibitor
Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and
Techniques: Expressing, Western Blot, Analysis, Transfection, Plasmid Preparation, Control, Over Expression, Knock-Out, Activation Assay
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma
doi: 10.1186/s13046-026-03792-6
Figure Lengend Snippet: SAA1 reshapes the tumor microenvironment by promoting macrophage recruitment and pro-tumorigenic polarization. A - B Representative immunofluorescence images ( A ) and corresponding quantification ( B ) of F4/80⁺ (green) and CD206⁺ (yellow) macrophages in tumors from PC-9 OR CDX models treated with vehicle or osimertinib, comparing vector control and SAA1-KO groups. Scale bar, 20 μm. C - D Flow cytometry plots ( D ) and statistical quantification ( C ) of M2 macrophage polarization (CD206⁺) in BMDM and THP-1 cells treated with PBS or exogenous SAA1 (100 ng/ml, 24 h). E qPCR analysis of classical M2 macrophage markers ( CD206 , VEGFA , TGFB1 , IL-10 , ARG1 ) in THP-1 and BMDM cells co-cultured with PC-9 OR cell lines under osimertinib treatment, comparing vector control and SAA1 knockout conditions ( n = 3). F qPCR analysis of newly proposed macrophage markers ( SPP1 , C1QC , ISG15 , FN1 ) in THP-1 and BMDM cells after exposure to exogenous SAA1(100 ng/ml, 24 h) ( n = 3). G qPCR analysis of M2 markers and SPP1 in THP-1 and BMDM cells treated with TAK-242 (10 µM, 24 h), with or without exogenous SAA1 (100 ng/ml, 24 h) ( n = 3). H - I Flow cytometry analysis ( H ) and comprehensive quantification ( I ) of CD206⁺ macrophages in THP-1 cells treated with PBS or exogenous SAA1 (100 ng/ml, 24 h), combined with DMSO, TAK-242 (10 µM, 24 h), or C29 (50 µM, 24 h), demonstrating the comparative blockade efficacy of distinct TLR pathways ( n = 3). J - L Representative multiplex immunofluorescence images ( L ) and quantitative analysis ( J , K ) of CD68⁺ (red), CD206⁺ (green), and SPP1⁺ (yellow) macrophage infiltration in paired LUAD patient samples before (TKI-naïve) and after (TKI-residual) osimertinib therapy. Scale bar, 50 μm. Student’s t-tests were for panels C , F , J , K and one-way or two-way ANOVA with Dunnett’s multiple comparison tests were for panels B, E, G, I. Abbreviations: OR, osimertinib-resistant; SAA1-KO, SAA1 knockout; Exo, exogenous; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry
Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and
Techniques: Immunofluorescence, Plasmid Preparation, Control, Flow Cytometry, Analysis, Cell Culture, Knock-Out, Multiplex Assay, Comparison, Immunohistochemistry, Co-Culture
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma
doi: 10.1186/s13046-026-03792-6
Figure Lengend Snippet: GATAD2A S114 phosphorylation modulates NuRD complex integrity and regulates SAA1 expression. A DNA pull-down assay using a biotin-labeled SAA1 promoter probe (-1000 to + 200 bp) incubated with PC-9 nuclear extracts. Mass spectrometry identified 41 transcription factors, five of which (RXRA, YY1, ETV6, MAX, GATAD2A) were selected based on ENCODE ChIP-seq data. B qPCR of SAA1 expression following two individual siRNA knockdown of the five candidate transcription factors in PC-9 cells ( n = 3). C , D qPCR and western blot of SAA1 levels in PC-9 and H1975 cells transfected with two independent siRNAs targeting GATAD2A ( n = 3). E Predicted GATAD2A binding motif and binding peaks in the SAA1 promoter region from public ChIP-seq datasets, with indicated the location of the primer used for ChIP-qPCR validation. F ChIP-qPCR of GATAD2A occupancy at the SAA1 promoter in PC-9 and H1975 cells compared with IgG controls ( n = 3). G Luciferase reporter assay of wild-type and mutant SAA1 promoters in PC-9 and H1975 cells following GATAD2A knockdown ( n = 3). H Phosphoproteomic mapping of GATAD2A in PC-9 parental and OR cells, showing phosphorylated residues including S107, S110 and S114, among which S114 was predicted to be phosphorylated by ERK. I SAA1 expression in PC-9 and H1975 cells harboring the GATAD2A S114A knock-in compared with wild-type cells following osimertinib treatment (10 nM, 48 h). J Co-immunoprecipitation analysis of GATAD2A interactions with MBD2 and MTA2 in PC-9 and H1975 cells under different treatments, including osimertinib (10 nM, 48 h), SCH772984 (ERK inhibitor) (10 µM, 48 h), and S114A mutation. K Quantitative analysis of the PLA signals representing GATAD2A-NuRD complex interactions in PC-9 and H1975 cells under the indicated conditions ( n = 3). L PLA showing GATAD2A-NuRD component interactions under the same conditions as panel J . Dunnett’s multiple comparison tests were applied for panels B , C , G , and K ; Student’s t-test for panel F . Abbreviations: TF, transcription factors; ChIP, chromatin immunoprecipitation; PLA, proximity ligation assay; NuRD, nucleosome remodeling and deacetylase complex
Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and
Techniques: Phospho-proteomics, Expressing, Pull Down Assay, Labeling, Incubation, Mass Spectrometry, ChIP-sequencing, Knockdown, Western Blot, Transfection, Binding Assay, ChIP-qPCR, Biomarker Discovery, Luciferase, Reporter Assay, Mutagenesis, Knock-In, Co-Immunoprecipitation Assay, Analysis, Comparison, Chromatin Immunoprecipitation, Proximity Ligation Assay, Histone Deacetylase Assay
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma
doi: 10.1186/s13046-026-03792-6
Figure Lengend Snippet: Preclinical evaluation of Anti-SAA1 neutralization in EGFR-mutant models. A Proliferation curves of PC-9 OR and H1975 OR cells treated with Anti-SAA1 (1 µg/mL) or isotype IgG control across the indicated time points ( n = 3). B Relative cell viability of PC-9 OR and H1975 OR cells following Anti-SAA1 (1 µg/mL) or IgG treatment ( n = 3). C - D Representative tumor images ( C ) and tumor growth curves ( D ) of PC-9 OR -derived CDX models treated with control therapy, Anti-SAA1, osimertinib, or the combination ( n = 6). Mice were administered daily oral gavage of osimertinib (5 mg/kg) or saline for nine consecutive days. In parallel, intraperitoneal injections of Anti-SAA1 (0.25 µg/g) or control IgG were given every three days ( n = 6). E Morphological features of PDOs treated with IgG, Anti-SAA1 (1 µg/mL) combined with either saline or osimertinib (10 nM). Scale bar, 20 μm. F ATP levels in corresponding PDOs under the indicated treatment conditions ( n = 3). G Representative tumor images of PDX models treated with control therapy, Anti-SAA1, osimertinib, or the combination ( n = 3 for each PDX). H Schematic of tumor induction in the h EGFR L858R/T790M genetically engineered mouse model using intratracheal AAV- Scgb1a1 -Cre delivery. I Micro-CT-based quantification of tumor burden after 4 weeks since treatment with osimertinib alone, Anti-SAA1 plus osimertinib, or isotype control. 30-days after AAV delivery, mice were administered osimertinib (5 mg/kg) or saline by daily oral gavage for 21 consecutive days. In addition, intraperitoneal injections of Anti-SAA1 (0.25 µg/g) or control IgG were given every three days, for a total of six doses. J Survival curves of mice receiving the indicated treatments ( n = 6). K Representative immunohistochemical and multiplex immunofluorescence images of lung tumor sections derived from immunocompetent GEMM models following the indicated treatments. DAPI (blue), F4/80 (magenta), CD206 (green), SPP1 (red), and CD8 (yellow). Scale bars, 50 μm. L - M Quantitative analyses of the percentage of immunosuppressive SPP1 + CD206 + subpopulations among total F4/80 + macrophages ( L ) and the infiltration rate of CD8 + T cells among total DAPI + cells ( M ) in the spontaneous tumor tissues ( n = 6). Two-way ANOVA for panels A , B , and D ; Dunnett’s multiple comparison test was applied for panel F , log-rank test for panel J , and one-way ANOVA for panels L and M . Abbreviations: Anti-SAA1, SAA1 neutralizing antibody; OR, osimertinib-resistant; CDX, cell-derived xenograft; PDO, patient-derived organoid; PDX, patient-derived xenograft; AAV, adeno-associated virus; micro-CT, micro-computed tomography
Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and
Techniques: Neutralization, Mutagenesis, Control, Derivative Assay, Saline, Micro-CT, Immunohistochemical staining, Multiplex Assay, Immunofluorescence, Comparison, Xenograft Assay, Virus
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma
doi: 10.1186/s13046-026-03792-6
Figure Lengend Snippet: Schematic representation illustrating the mechanism of the ERK/GATAD2A/SAA1 axis in driving osimertinib resistance in EGFR-mutated lung adenocarcinoma. The targeted inhibition of mutant EGFR by osimertinib suppresses downstream ERK signaling. This reduction in ERK kinase activity leads to the dephosphorylation of the epigenetic regulator GATAD2A at the S114 site. In its dephosphorylated state, GATAD2A fails to maintain the assembly of the NuRD corepressor complex at the SAA1 promoter. The dissociation of the NuRD complex relieves the epigenetic silencing of the SAA1 gene, resulting in robust transcriptional derepression and the subsequent secretion of SAA1 protein into the extracellular space. Once secreted, SAA1 functions as a dual-modal mediator to orchestrate acquired resistance. Autocrinely, SAA1 binds to TLR4 on the tumor cell membrane, triggering the intracellular NF-κB signaling cascade to promote tumor cell survival and persistence. Paracrinely, SAA1 remodels the tumor microenvironment by promoting the polarization of macrophages toward an immunosuppressive pro-tumor phenotype. Therapeutic intervention with an anti-SAA1 neutralizing antibody effectively intercepts these extracellular signals, abrogating both the tumor-intrinsic NF-κB survival pathway and the macrophage-mediated immune evasion, thereby restoring sensitivity to osimertinib
Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and
Techniques: Inhibition, Mutagenesis, Activity Assay, De-Phosphorylation Assay, Membrane, Sensitivity
Journal: International journal of oncology
Article Title: C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma.
doi: 10.3892/ijo.2015.3042
Figure Lengend Snippet: Figure 3. Elisa verification and immunohistochemistry of CRP, C9 and SAA. (A) ELISA verification of iTRAQ results. Samples tested were the same as those used in the iTRAQ experiments. (B) Cohort verification with ELISA. Plasma concentrations of CRP, C9 and SAA were determined in 284 plasma samples. (C) Human tissue microarray and immunohistochemical analysis of CRP, C9 and SAA proteins in cirrhotic and HCC tissues. Scale bar, 100 µm. Data are shown as mean ± SD, *p<0.05.
Article Snippet: The
Techniques: Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Multiplex sample analysis, Clinical Proteomics, Microarray, Immunohistochemical staining
Journal: Frontiers in Endocrinology
Article Title: Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands
doi: 10.3389/fendo.2023.1119227
Figure Lengend Snippet: Amino acid sequence of naturally occurring and commercially available recombinant human A-SAA preparations discussed in the present paper.
Article Snippet:
Techniques: Sequencing, Recombinant
Journal: The Journal of Clinical Investigation
Article Title: SAA1/FPR2 signaling between keratinocytes and neutrophils sustains chronic inflammation in Sweet syndrome
doi: 10.1172/JCI193566
Figure Lengend Snippet: ( A ) Ligand-receptor analysis reveals keratinocyte- and neutrophil-specific interactions. Keratinocytes expressed SAA1 transcripts and neutrophils expressed the FPR2 receptor (red dot, right-most column). ( B ) Dot plot demonstrating predominantly cell-specific expression of SAA1 and FPR2 transcripts. The dot size reflects the percentage of cells expressing the gene, and the color illustrates the level of gene expression. ( C ) Representative immunofluorescence staining images and quantification from 5 diseased and 5 control samples, confirming the expression of SAA1 and FPR2 in keratinocytes and neutrophils, respectively. Scale bars: 100 μm. ( D ) Dot plot comparing keratinocyte SAA1 and the control gene DEFB1 in different inflammatory skin conditions. The dot size reflects the percentage of cells expressing the gene, and the color illustrates the level of gene expression. ( E ) SAA1 secretion measured by ELISA in healthy neutrophils or healthy neutrophils exposed to keratinocytes. ( F ) Antibodies blocking SAA1 and FPR2 restored long-lived neutrophil lifespan to WT neutrophil levels. ( G ) Recombinant human SAA1 increased neutrophil survival at 72 hours ( n = 3 independent donors). Data indicate the mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001, by 2-tailed, unpaired Student’s t test ( E and G ) and 1-way ANOVA with individual comparisons ( F ).
Article Snippet: Freshly isolated neutrophils from healthy donors were treated with recombinant
Techniques: Expressing, Gene Expression, Immunofluorescence, Staining, Control, Enzyme-linked Immunosorbent Assay, Blocking Assay, Recombinant
Journal: Clinical and Translational Medicine
Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer
doi: 10.1002/ctm2.70698
Figure Lengend Snippet: Identification of SAA1‐associated metastatic epithelial subpopulations in ovarian cancer by scRNA‐seq. (A) t‐SNE visualization of cells from paired primary tumours and peritoneal metastases of two patients. (B) Distribution of the ten epithelial clusters in Pri and Meta samples, shown separately. (C) Relative proportions of the ten epithelial clusters in Pri and Meta samples. (D) Pseudotime analysis of epithelial cells from metastases. Left: cells ordered along the inferred trajectory from early (dark) to late (light); the black line indicates the main lineage with bifurcation. Right: same embedding coloured by clusters (0–9). (E) Dot plot showing representative gene expression across the ten clusters; dot size indicates the fraction of expressing cells, and colour denotes average expression. (F) KEGG enrichment of clusters 0, 2, 4 and 6 based on cluster‐specific marker genes. (G) Representative TMA cores stained for SAA1 (green) and nuclei (blue). Scale bar, 200 µm. Quantification of SAA1 + cell percentage in Pri and Meta TMA cores is shown as violin plots with overlaid box plots (Pri, n = 81; Meta, n = 93). p value was determined by the Wilcoxon rank‐sum test, p = 2.9 × 10 − 1 6 . (H) t‐SNE plots showing SAA1 expression in primary (pri) and metastatic (meta) ovarian cancer cells. (I) Kaplan–Meier survival curves in the TCGA‐OV cohort ( n = 429) according to SAA1 expression (log‐rank p = 0.0075). (J) Multivariate Cox regression forest plot identifying independent prognostic factors for ovarian cancer, including SAA1 expression and clinicopathological variables.
Article Snippet:
Techniques: Gene Expression, Expressing, Marker, Staining
Journal: Clinical and Translational Medicine
Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer
doi: 10.1002/ctm2.70698
Figure Lengend Snippet: Tumour‐derived SAA1 does not directly promote tumour cell proliferation or migration but drives epithelial–macrophage crosstalk. (A) Colony formation assay after 14 days of culture comparing SKOV3 Cas9 WT vs. SKOV3 SAA1–/– and OVCAR3 Cas9 WT versus OVCAR3 SAA1–/– . (B) EdU staining of WT and SAA1‐KO ovarian cancer cells (SKOV3 and OVCAR3). Representative images showing Hoechst‐labelled nuclei (blue) and EdU‐positive proliferating cells (green). Scale bar, 20 µm. (C) Wound‐healing assays of WT and SAA1‐KO ovarian cancer cells (SKOV3 and OVCAR3). Representative images at 0, 24 and 48 h with quantification of relative migration rate. Scale bar, 100 µm. (D) Subcutaneous tumour growth of WT and SAA1‐KO SKOV3 cells in BALB/c nude mice. Representative tumours and growth curves showing no significant difference (ns). Data represent mean ± SD ( n = 4). (E) Overall cell–cell interaction network showing communication strength among major cell types in primary ovarian tumours. (F) CellChat analysis of SAA pathway activity in primary HGSOC. (G) Ligand–receptor interactions of SAA1 signalling between epithelial cells and macrophage subsets. (H) Comparison of EMT state composition between primary (pri) and metastatic (meta) tumours. Quantitative data are shown as mean ± SD. Statistical significance in A–C was assessed using unpaired two‐tailed Student’s t ‐test for the indicated comparisons; tumor growth curves in D were analyzed by two‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Article Snippet:
Techniques: Derivative Assay, Migration, Colony Assay, Staining, Activity Assay, Comparison, Two Tailed Test
Journal: Clinical and Translational Medicine
Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer
doi: 10.1002/ctm2.70698
Figure Lengend Snippet: Tumour‐derived SAA1 promotes macrophage‐mediated tumour cell migration and EMT through the SAA1–FPR2 axis. (A) Schematic of the indirect Transwell co‐culture system, with ovarian cancer cells (SKOV3 or OVCAR3; WT or SAA1–/–) seeded in the upper inserts and macrophages (Mø) in the lower chambers. (B) Transwell migration of OVCAR3 and SKOV3 cells with or without macrophages, with representative images and quantification of relative migration rates, n = 3. Scale bar, 50 µm. (C) Migration assays of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells co‐cultured with macrophages under different conditions, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (D) Schematic of a three‐stage cascade co‐culture model: (i) tumour‐conditioned medium (TCM) from WT or SAA1–/– SKOV3 cells; (ii) macrophages exposed to TCM for 24 h to generate tumour‐educated macrophage conditioned medium (TeMCM); (iii) TeMCM applied to ovarian cancer organoids/tumour cells. (E) CMFDA‐stained ovarian cancer organoids cultured with TeMCM from WT or KO SKOV3 cells, n = 3. Scale bar, 100 µm. (F) Ovarian cancer organoids cultured under indicated conditions, stained for E‐cadherin (green), vimentin (cyan), pan‐CK (magenta), and nuclei (blue). CMFDA and H&E staining show viability and morphology. Scale bar, 100 µm. (G) Immunofluorescence of SKOV3 cells treated with TeMCM, stained for nuclei (blue), E‐cadherin (green), and vimentin (red). Scale bar, 10 µm. (H) Quantification of fluorescence intensity in G. (I) Western blot analysis of E‐cadherin and vimentin in SKOV3 cells under different MCM or TeMCM treatments. Quantitative data in B, C and H are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by Student's t ‐test in B and by one‐way ANOVA with multiple comparisons test in C and H. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Article Snippet:
Techniques: Derivative Assay, Migration, Co-Culture Assay, Cell Culture, Staining, Immunofluorescence, Fluorescence, Western Blot
Journal: Clinical and Translational Medicine
Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer
doi: 10.1002/ctm2.70698
Figure Lengend Snippet: SAA1–FPR2 axis drives macrophage recruitment and polarization. (A) Macrophage migration under WTCM (SKOV3 Cas9 WT CM), KOCM (SKOV3 SAA1–/– CM), recombinant SAA1, and/or FPR2 inhibitor WRW4. Representative images (left) and quantification (right). Scale bar, 50 µm. (B) Representative tumour sections from two patients stained for Pan‐CK (red), SAA1 (green), CD68 (cyan), FPR2 (grey), and DAPI (blue), with merged images shown. Scale bar, 20 µm. (C) Representative images showing morphological changes in THP‐1–derived macrophages under the indicated culture conditions. Scale bar, 100 µm. (D) Immunofluorescence staining of THP‐1–derived macrophages under the indicated culture conditions. CD86 (green), CD206 (red), and nuclei (DAPI, blue). Scale bar, 10 µm. (E) Representative flow cytometry plots and quantification of CD206 + macrophages under different treatments, including control medium, recombinant SAA1, FPR2 antagonist WRW4, and conditioned media from SKOV3 Cas9 WT (WTCM) or SKOV3 SAA1–/– (KOCM), n = 3. (F) Multiplex immunofluorescence staining of SAA1 (green), CD68 (cyan), CD206 (red) and DAPI (blue) in ovarian cancer tissues. Scale bars, 300 µm. Quantitative data in A, D and E are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Article Snippet:
Techniques: Migration, Recombinant, Staining, Derivative Assay, Immunofluorescence, Flow Cytometry, Control, Multiplex Assay
Journal: Clinical and Translational Medicine
Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer
doi: 10.1002/ctm2.70698
Figure Lengend Snippet: SAA1–FPR2 axis drives CXCL1 production in macrophages via JAK2–STAT3 signalling. (A) Proteomic profiling of secreted factors in TeMCM generated with TCM from SKOV3 Cas9 WT versus SKOV3 SAA1–/– cells. (B) KEGG pathway enrichment (bubble plot) of DEGs from macrophages exposed to SKOV3 Cas9 WT versus SKOV3 SAA1–/– TCM. (C) Heatmap of cytokine/chemokine‐related DEGs from RNA‐seq of macrophages educated with SKOV3 Cas9 WT TCM (A1–A3) or SKOV3 SAA1–/– TCM (B4–B6). (D) Venn diagram showing overlap of upregulated genes from RNA‐seq and proteomics. The 38 shared genes are listed below. (E) Differential expression of the 38 overlapping genes. (F) CXCL1 expression in macrophages under different treatments. Upper: densitometric quantification; lower: representative immunoblots. (G) ELISA quantification of CXCL1 in macrophage supernatants under indicated treatments, n = 3. (H) Predicted STAT3‐binding sites within the CXCL1 promoter (−2000 bp to TSS) are shown, along with the consensus STAT3 motif. (I) ChIP–qPCR showing STAT3 enrichment at nine predicted binding sites on the CXCL1 promoter in macrophages treated with SKOV3 Cas9 WT TCM, SKOV3 SAA1–/– TCM, or SKOV3 SAA1–/– TCM + rSAA1. (J) Dual‐luciferase assay of CXCL1 promoter activity upon STAT3 overexpression, n = 3. Reporter groups: empty vector, CXCL1 WT promoter, STAT3 + WT, and STAT3 + MUT. (K) Immunoblot of p‐JAK2, JAK2, p‐STAT3, STAT3, and CXCL1 in macrophages treated with SKOV3 Cas9 WT or SKOV3 SAA1–/– TCM with or without WRW4, rSAA1, Fedratinib, or Stattic. Quantitative data in F, G, I and K are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Article Snippet:
Techniques: Generated, RNA Sequencing, Quantitative Proteomics, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Binding Assay, ChIP-qPCR, Luciferase, Activity Assay, Over Expression, Plasmid Preparation
Journal: Clinical and Translational Medicine
Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer
doi: 10.1002/ctm2.70698
Figure Lengend Snippet: CXCL1 enhances the invasive and metastatic potential of ovarian cancer cells. (A–B) Wound‐healing assays of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with rCXCL1 or PBS, n = 3. Representative images (left) and quantification of migration rate (right). Scale bar, 100 µm. (C) Transwell migration of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with rCXCL1 or PBS, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (D) Matrigel invasion assay of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells with rCXCL1 or PBS, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (E) Left: schematic illustration of the inverse invasion model; middle: laser‐induced fluorescence imaging; right: quantitative analysis of the effect of CXCL1 on SKOV3‐GFP invasion. (F) Representative three‐dimensional reconstruction based on Z‐stack scanning, presented as a depth‐coded heatmap. (G) Immunoblot of E‐cadherin and vimentin in SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with PBS or rCXCL1. (H) Immunoblot of E‐cadherin, β‐catenin, and vimentin in SKOV3 cells treated with increasing concentrations of rCXCL1 (0–100 ng/mL, 24 h). (I) Representative tissue microarray (TMA) cores stained for CXCL1 by immunohistochemistry. Scale bar, 2 mm. Kaplan–Meier overall survival analysis of the same cohort stratified by CXCL1 IHC score (High vs Low). Log‐rank p = 0.029. (J) Kaplan–Meier analysis of TCGA‐OV cohort stratified by CXCL1 mRNA expression (High vs Low). Log‐rank p = 0.0083; HR = 1.60, 95% CI 1.13–2.27. Quantitative data in A–E are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by Student's t ‐test in A–D and by one‐way ANOVA in E. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Article Snippet:
Techniques: Migration, Invasion Assay, Fluorescence, Imaging, Western Blot, Microarray, Staining, Immunohistochemistry, Expressing
Journal: Clinical and Translational Medicine
Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer
doi: 10.1002/ctm2.70698
Figure Lengend Snippet: Inhibition of the SAA1–TAM–CXCL1 axis suppresses ovarian cancer metastasis. (A) Experimental scheme for the C57BL/6 mouse model of ovarian cancer peritoneal dissemination. (B) Western blot of SAA1 in luciferase‐labelled ID8 cells. Protein levels were compared between shSAA1‐ID8‐LUC and shCtrl‐ID8‐LUC. (C) Bioluminescence imaging at Week 7 after intraperitoneal injection of ID8‐LUC or shSAA1‐ID8‐LUC cells, treated with control liposomes (Ctrl Lip), clodronate liposomes (CLO Lip), vehicle (DMSO), or the CXCL1 receptor inhibitor SB225002, n = 4. (D) Quantification of average luminescence intensity. (E) Immunohistochemistry of F4/80 in spleen sections from mice bearing shCtrl‐ID8‐LUC or shSAA1‐ID8‐LUC tumours, with or without Ctrl Lip, CLO Lip, DMSO, or SB225002. Left: representative fields from red pulp; right: quantification of F4/80 + area ratio (%). Scale bar, 100 µm. (F) Multiplex immunofluorescence of peritoneal tumour sections under the indicated interventions. Staining includes Pan‐CK (red), SAA1 (green), F4/80 (cyan), CD206 (magenta), CXCL1 (grey), and nuclei (blue). Merged images are shown in the bottom row. Scale bar, 20 µm. Quantitative data in D–F are shown as mean ± SD. Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Article Snippet:
Techniques: Inhibition, Western Blot, Luciferase, Imaging, Injection, Control, Liposomes, Immunohistochemistry, Multiplex Assay, Immunofluorescence, Staining
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
doi: 10.1186/s13046-025-03536-y
Figure Lengend Snippet: Increased MDSCs and SAA1 expression associated with ovarian cancer. ( A ) Flow cytometry analysis of M-MDSCs in PBMCs from patients with benign and malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( B ) Flow cytometry analysis of PMN-MDSCs in PBMCs from patients with benign or malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( C ) Flow cytometry analysis of M-MDSCs in tumor-infiltrating immune cells from patients with benign or malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( D ) Flow cytometry analysis of PMN-MDSCs in tumor-infiltrating immune cells from patients with benign or malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( E ) Flow cytometry analysis of Treg cells in PBMCs from patients with benign or malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( F ) qRT-PCR analysis of the mRNA expression levels of iNOS, IDO and Arg-1 in tumor tissues from patients with benign or malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( G ) Heatmap showing the top upregulated differentially expressed genes following co-culture of SKOV3 cells and MDSCs based on analysis of the GSE145374 dataset. ( H ) SAA1 expression in ovarian cancer tissues based on the GEPIA database. Each dot represents one sample; data are presented as mean ± SEM; unpaired two-tailed Student’s t-test. ( I ) Kaplan–Meier analysis of overall survival in ovarian cancer patients stratified by SAA1 expression using GEPIA. Log-rank test. ( J ) Detection of SAA1 mRNA expression in benign and malignant ovarian tumor tissues by qRT-PCR. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( K ) Detection of SAA1 protein levels in serum from patients with benign and malignant ovarian tumors by ELISA. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( L ) Association between SAA1 expression and FIGO stage in ovarian cancer based on the public GSE51088 dataset. Each dot represents one sample; Mann–Whitney U test. ( M ) Association between SAA1 expression and histological grade in ovarian cancer based on the public GSE63885 dataset. Each dot represents one sample; Kruskal–Wallis test. ( N ) SAA1 protein expression in paired tumor (T) and adjacent paracancerous (P) tissues assessed by Western blotting (left) and densitometric analysis (right). Each dot represents an individual patient; paired two-tailed Student’s t-test. ( O ) Localization and expression of SAA1 in tumor and paracancerous tissues detected by immunohistochemistry ( n = 3). Representative images are presented at 100× and 400× magnification. ( P ) SAA1 mRNA expression in normal ovarian epithelial cells and ovarian cancer cell lines assessed by qRT-PCR. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( Q ) Detection of SAA1 protein expression in normal ovarian epithelial cells and ovarian cancer cell lines by Western blotting (left) and densitometric analysis (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. *Statistical significance: * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
Article Snippet: The
Techniques: Expressing, Flow Cytometry, MANN-WHITNEY, Quantitative RT-PCR, Co-Culture Assay, Two Tailed Test, Enzyme-linked Immunosorbent Assay, Western Blot, Immunohistochemistry
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
doi: 10.1186/s13046-025-03536-y
Figure Lengend Snippet: SAA1 promotes the proliferation of ovarian cancer cells in vitro. ( A ) Detection of SAA1 knockdown efficiency at the mRNA level in A2780 cells by qRT-PCR. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( B–C ) Detection of SAA1 knockdown efficiency at the protein level in A2780 cells by Western blotting ( B ) and densitometric analysis ( C ). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( D ) Detection of SAA1 overexpression efficiency at the mRNA level in SKOV3 cells by qRT-PCR. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. ( E–F ) Detection of SAA1 overexpression efficiency at the protein level in SKOV3 cells by Western blotting ( E ) and densitometric analysis ( F ). Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. ( G ) Detection of secreted SAA1 levels in the supernatant of A2780 cells after SAA1 knockdown by ELISA. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( H ) Detection of secreted SAA1 levels in the supernatant of SKOV3 cells after SAA1 overexpression by ELISA. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. ( I ) CCK8 assay to evaluate the effect of SAA1 knockdown on A2780 cell proliferation. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( J ) CCK8 assay to evaluate the effect of SAA1 overexpression on SKOV3 cell proliferation. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. ( K–L ) EdU assay to evaluate the proliferative capacity of A2780 cells following SAA1 knockdown. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( M–N ) EdU assay to evaluate the proliferative capacity of SKOV3 cells following SAA1 overexpression. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. ( O–P ) Colony formation assay to assess the clonogenic capacity of A2780 cells following SAA1 knockdown. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( Q–R ) Colony formation assay to assess the clonogenic capacity of SKOV3 cells following SAA1 overexpression. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. *Statistical significance: * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, not significant
Article Snippet: The
Techniques: In Vitro, Knockdown, Quantitative RT-PCR, Western Blot, Over Expression, Two Tailed Test, Enzyme-linked Immunosorbent Assay, CCK-8 Assay, EdU Assay, Colony Assay
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
doi: 10.1186/s13046-025-03536-y
Figure Lengend Snippet: SAA1 promotes the proliferation and metastasis of ovarian cancer in vivo and in vitro. ( A–C ) Transwell assay to evaluate the migration and invasion capacity of A2780 cells following SAA1 knockdown. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( D–F ) Transwell assay to evaluate the migration and invasion capacity of SKOV3 cells following SAA1 overexpression. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. ( G–I ) Transwell assay to evaluate the migration and invasion capacity of ID8 cells following SAA1 knockdown. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-test. ( J ) Detection of EMT-related proteins (N-Cadherin, E-Cadherin, Vimentin, Snail) in A2780 cells following SAA1 knockdown by Western blotting (top) and densitometric analysis (bottom). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( K ) Detection of EMT-related proteins in SKOV3 cells following SAA1 overexpression by Western blotting (top) and densitometric analysis (bottom). Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-tests. ( L ) Detection of EMT-related proteins in ID8 cells following SAA1 knockdown by Western blotting (top) and densitometric analysis (bottom). Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-tests. ( M–N ) Luciferase-based in vivo imaging to evaluate the effect of SAA1 knockdown on ovarian cancer progression in tumor-bearing mice. Each dot represents one mouse; data are presented as mean ± SEM; unpaired two-tailed Student’s t-test. ( O ) Kaplan–Meier analysis to evaluate the effect of SAA1 knockdown on the survival duration of tumor-bearing mice. Log-rank test. ( P–Q ) Immunohistochemical detection of SAA1, Ki67, E-Cadherin, and N-Cadherin expression in abdominal wall tumors of tumor-bearing mice ( P ) and quantification of positive staining ( Q ). Data are presented as mean ± SEM from three mice per group; unpaired two-tailed Student’s t-tests. *Statistical significance: * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
Article Snippet: The
Techniques: In Vivo, In Vitro, Transwell Assay, Migration, Knockdown, Over Expression, Two Tailed Test, Western Blot, Luciferase, In Vivo Imaging, Immunohistochemical staining, Expressing, Staining
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
doi: 10.1186/s13046-025-03536-y
Figure Lengend Snippet: SAA1 recruits MDSCs and promotes MDSCs differentiation in ovarian cancer. ( A ) Relationship between SAA1 expression and immune infiltration in ovarian cancer analyzed using the CIBERSORT algorithm based on TCGA data. ( B ) Correlation between SAA1 expression and the infiltration of different immune cell subsets in ovarian cancer using the CIBERSORT algorithm based on TCGA data. ( C–E ) Correlation analysis between SAA1 expression and CD33 ( C ), S100A8 ( D ), or CD14 ( E ) expression in ovarian cancer using the TIMER database; Spearman’s rank correlation test. ( F ) Schematic diagram of MDSCs recruitment and pro-GMP differentiation experiments. ( G–H ) Co-culture assays to detect the ability of supernatants from A2780 cells with SAA1 knockdown to recruit MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( I–J ) Co-culture assays to detect the ability of supernatants from ID8 cells with SAA1 knockdown to recruit MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( K–L ) Co-culture assays to detect the ability of supernatants from SKOV3 cells with SAA1 overexpression to recruit MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( M–N ) Flow cytometry to detect the ability of supernatants from A2780 cells with SAA1 knockdown to promote the differentiation of GMPs to MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( O–P ) Flow cytometry to detect the ability of supernatants from SKOV3 cells with SAA1 overexpression to promote the differentiation of GMPs to MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. *Statistical significance: ** P < 0.01; *** P < 0.001; **** P < 0.0001
Article Snippet: The
Techniques: Expressing, Co-Culture Assay, Knockdown, Over Expression, Flow Cytometry
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
doi: 10.1186/s13046-025-03536-y
Figure Lengend Snippet: SAA1 released by ovarian cancer cells recruits MDSCs and promotes MDSCs differentiation via TLR2/4. ( A – B ) Flow cytometry analysis of TLR2 expression on the surface of PMN-MDSCs ( A ) and M-MDSCs ( B ) from the peripheral blood of patients with benign or malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( C–D ) Flow cytometry analysis of TLR4 expression on the surface of PMN-MDSCs ( C ) and M-MDSCs ( D ) from the peripheral blood of patients with benign or malignant ovarian tumors. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( E–F ) Correlation analysis between SAA1 expression and TLR2 ( E ) or TLR4 ( F ) expression in ovarian cancer using the TIMER database; Spearman’s rank correlation test. ( G–H ) Rescue experiments assessing the effect of adding recombinant SAA1 protein or the TLR2/4 inhibitor SsnB on the ability of A2780 cell supernatants to recruit MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Tukey’s multiple comparisons test. ( I–J ) Rescue experiments assessing the effect of recombinant SAA1 protein or SsnB on the ability of ID8 cell supernatants to recruit MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Tukey’s multiple comparisons test. ( K–L ) Rescue experiments assessing the effect of adding recombinant SAA1 protein or SsnB on the ability of A2780 cell supernatants to induce GMP differentiation into MDSCs. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Tukey’s multiple comparisons test. *Statistical significance: * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, not significant
Article Snippet: The
Techniques: Flow Cytometry, Expressing, MANN-WHITNEY, Recombinant
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
doi: 10.1186/s13046-025-03536-y
Figure Lengend Snippet: SAA1–mediated IL-1β release from MDSCs enhances SAA1 expression in ovarian cancer via the IL-1β/IL-1R/NF-κB axis. ( A ) Cytokine expression profile in MDSCs following SAA1 stimulation, detected by qRT-PCR. Data are presented as mean ± SEM from five independent experiments; unpaired two-tailed Student’s t-test. ( B ) Correlation analysis between SAA1 and IL1B expression in ovarian cancer using the TIMER database; Spearman’s rank correlation test. ( C ) IL-1β expression and secretion in MDSCs after SAA1 treatment across time points (0, 6, 12, 24 h), detected by qRT-PCR (left) and ELISA (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( D ) IL-1β expression and secretion in MDSCs after adding the TLR2/4 inhibitor SsnB to SAA1 treatment, detected by qRT-PCR (left) and ELISA (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( E ) SAA1 expression and secretion in SKOV3 cells after IL-1β treatment across time points (0, 6, 12, 24 h), detected by qRT-PCR (left) and ELISA (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( F ) Detection of SAA1 protein expression in SKOV3 cells after IL-1β treatment across time points (0, 6, 12, 24 h) by Western blotting (left) and densitometric analysis (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( G ) Prediction of transcription factors binding to the SAA1 promoter using TFDB, GTRD, and JASPAR databases. ( H ) Expression of predicted transcription factors in SKOV3 cells with or without IL-1β treatment, detected by qRT-PCR. Data are presented as mean ± SEM from three independent experiments; unpaired two-tailed Student’s t-tests. ( I ) SAA1 expression and secretion in SKOV3 cells after adding the NF-κB inhibitor APDC to IL-1β treatment, detected by qRT-PCR (left) and ELISA (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( J ) SAA1 expression and secretion in SKOV3 cells after adding the IL-1 receptor antagonist (IL-1RA) to IL-1β treatment, detected by qRT-PCR (left) and ELISA (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( K ) Detection of NF-κB signaling molecules in SKOV3 cells after adding APDC to IL-1β treatment by Western blotting (left) and densitometric analysis (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( L ) Detection of NF-κB signaling molecules in SKOV3 cells after adding IL-1RA to IL-1β treatment by Western blotting (left) and densitometric analysis (right). Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( M ) ChIP assay to detect the binding of transcription factor P65 to the SAA1 promoter in SKOV3 cells. Data are presented as mean ± SEM from three independent experiments; one-way ANOVA followed by Dunnett’s multiple comparisons test. ( N ) IL1B expression in ovarian cancer tissues based on the GEPIA database. Each dot represents one sample; data are presented as mean ± SEM; unpaired two-tailed Student’s t-test. ( O ) Association between IL1B expression and FIGO stage in ovarian cancer based on the GSE51088 dataset. Each dot represents one sample; Mann–Whitney U test. ( P ) Association between IL1B expression and histological grade in ovarian cancer based on the GSE63885 dataset. Each dot represents one sample; Kruskal–Wallis test. ( Q ) Detection of IL1B mRNA expression in benign and malignant ovarian tumor tissues by qRT-PCR. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. ( R ) Detection of IL-1β protein levels in serum from patients with benign and malignant ovarian tumors by ELISA. Each dot represents an individual patient; data are presented as mean ± SEM; Mann–Whitney U test. *Statistical significance: * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, not significant
Article Snippet: The
Techniques: Expressing, Quantitative RT-PCR, Two Tailed Test, Enzyme-linked Immunosorbent Assay, Western Blot, Binding Assay, MANN-WHITNEY
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
doi: 10.1186/s13046-025-03536-y
Figure Lengend Snippet: Deciphering the impact of SAA1-driven immunosuppression and its clinical relevance in ovarian cancer. ( A ) Abdominal circumference of C57BL/6 mice measured weekly for 4 weeks after intraperitoneal injection of SAA1-WT or SAA1-KO ID8 cells. Data are presented as mean ± SEM; two-way ANOVA. ( B ) Abdominal circumference at Week 4. Each dot represents one mouse; data are presented as mean ± SEM; unpaired two-tailed Student’s t-test. ( C ) Representative gross images showing differences in tumor nodule formation on the abdominal wall between SAA1-WT and SAA1-KO mice. ( D–E ) Detection of splenic G-MDSCs and M-MDSCs in SAA1-WT and SAA1-KO mice by flow cytometry ( D ) and quantification ( E ). Each dot represents one mouse; data are presented as mean ± SEM; unpaired two-tailed Student’s t-tests. ( F–G ) Detection of ascitic G-MDSCs and M-MDSCs in SAA1-WT and SAA1-KO mice by flow cytometry ( F ) and quantification ( G ). Each dot represents one mouse; data are presented as mean ± SEM; unpaired two-tailed Student’s t-tests. ( H ) Flow cytometry analysis of the number of Treg cells in the spleen and ascites of SAA1-WT and SAA1-KO mice. Each dot represents one mouse; data are presented as mean ± SEM; unpaired two-tailed Student’s t-test. ( I ) Flow cytometry to detect the ability of CD8⁺ T cells to secrete IFN-γ in the spleen and ascites of SAA1-WT and SAA1-KO mice. Each dot represents one mouse; data are presented as mean ± SEM; unpaired two-tailed Student’s t-test. ( J ) Flow cytometry to detect the ability of CD8⁺ T cells to secrete GZMB in the spleen and ascites of SAA1-WT and SAA1-KO mice. Each dot represents one mouse; data are presented as mean ± SEM; unpaired two-tailed Student’s t-test. ( K ) Representative multiplex immunofluorescence (mIF) images of tumor tissues from ovarian cancer patients with high or low SAA1 expression, with three patients in each group. ( L ) Correlation between SAA1 and CD33 expression in the GSE17260 , GSE32062 , and GSE51088 datasets; Spearman’s rank correlation test. ( M ) Correlation between SAA1 and IL1B expression in the GSE17260 , GSE32062 , and GSE51088 datasets; Spearman’s rank correlation test. ( N ) Kaplan–Meier analysis evaluating the prognostic value of SAA1 high CD33 high versus SAA1 low CD33 low expression for OS in TCGA-OC patients; log-rank test. ( O ) Kaplan–Meier survival analysis evaluating the prognostic value of SAA1 high IL1B high versus SAA1 low IL1B low expression for OS in TCGA-OC patients; log-rank test. ( P ) Kaplan–Meier survival analysis evaluating the prognostic value of the SAA1/IL1B/CD33 axis for OS in TCGA-OC patients; log-rank test. ( Q ) A nomogram constructed based on SAA1, IL1B, and CD33 expression from TCGA-OC data. ( R ) Schematic diagram showing how ovarian cancer cells form a positive feedback loop with MDSCs through the SAA1-IL-1β axis, promoting immune evasion. *Statistical significance: * P < 0.05; ** P < 0.01; **** P < 0.0001; ns, not significant
Article Snippet: The
Techniques: Injection, Two Tailed Test, Flow Cytometry, Multiplex Assay, Immunofluorescence, Expressing, Construct
Journal: Journal of Leukocyte Biology
Article Title: Effects of serum amyloid protein A on influenza A virus replication and viral interactions with neutrophils
doi: 10.1002/JLB.4AB0220-116RR
Figure Lengend Snippet: Human SAA and/or HDL proteins compared in this study †
Article Snippet: We tested several commercially available forms of SAA1, including native human serum SAA complexed with HDL (SAAHDL; Fisher Scientific), SAA (19‐94) isolated from human serum (Abcam; Cambridge, United Kingdom, Abcam.com),
Techniques: Sequencing, Recombinant
Journal: Journal of Leukocyte Biology
Article Title: Effects of serum amyloid protein A on influenza A virus replication and viral interactions with neutrophils
doi: 10.1002/JLB.4AB0220-116RR
Figure Lengend Snippet: Binding of SAA preparations to influenza A virus (IAV)—Binding of SAAs to the Phil82 strain of IAV was tested by ELISA as described in Section 2 (“Materials And Methods”) using an anti‐serum amyloid A (anti‐SAA1) antibody (panel A). Binding of SAA1 was also tested in presence of maltose (panel B) and using an anti‐DDK antibody for detection (SAA1 has a DDK tail) (panel C). HDL binding to IAV was tested as well (panel D). * = P < 0.05 and ** = P < 0.01 compared to control. Results represent mean ± sem for 3 to 5 experiments
Article Snippet: We tested several commercially available forms of SAA1, including native human serum SAA complexed with HDL (SAAHDL; Fisher Scientific), SAA (19‐94) isolated from human serum (Abcam; Cambridge, United Kingdom, Abcam.com),
Techniques: Binding Assay, Virus, Enzyme-linked Immunosorbent Assay, Control
Journal: Journal of Leukocyte Biology
Article Title: Effects of serum amyloid protein A on influenza A virus replication and viral interactions with neutrophils
doi: 10.1002/JLB.4AB0220-116RR
Figure Lengend Snippet: Neutralization of influenza A virus (IAV) by serum SAA, but not recombinant, SAA preparations—The indicated strains of IAV were pre‐incubated with SAA and or HDL preparations and then these were used to infection MDCK cell monolayers as described in Section 2 (“Materials And Methods”). Serum SAA from Abcam (panel A), SAA complexed with HDL (SAAHDL; panel B), serum HDL (panel C), and two recombinant serum amyloid A (SAA1) preparations were compared (panel D; HDL and SAAHDL included for comparison). * = P < 0.05 and ** = P < 0.01 and *** = < 0.001 compared to control. Results represent mean ± sem for 3 to 5 experiments
Article Snippet: We tested several commercially available forms of SAA1, including native human serum SAA complexed with HDL (SAAHDL; Fisher Scientific), SAA (19‐94) isolated from human serum (Abcam; Cambridge, United Kingdom, Abcam.com),
Techniques: Neutralization, Virus, Recombinant, Incubation, Infection, Comparison, Control
Journal: Journal of Leukocyte Biology
Article Title: Effects of serum amyloid protein A on influenza A virus replication and viral interactions with neutrophils
doi: 10.1002/JLB.4AB0220-116RR
Figure Lengend Snippet: Stimulation of neutrophil hydrogen peroxide production by SAA and or HDL—Neutrophil H 2 O 2 generation was measured through decline in scopoletin fluorescence as described in Section 2 (“Materials And Methods”). Influenza A virus (IAV; Phil82 strain) was pre‐incubated with the indicated concentrations of SAA and/or HDL preparations and added to suspensions of neutrophils at time 0. Results of unstimulated cells (PBS) are included for comparison. Instances where serum amyloid A (SAA1) proteins increased IAV‐induced H 2 O 2 production are noted by * or ** in in legend, where * = P < 0.05 and ** = P < 0.01 compared to control. Results represent mean ± sem for 3 to 5 experiments
Article Snippet: We tested several commercially available forms of SAA1, including native human serum SAA complexed with HDL (SAAHDL; Fisher Scientific), SAA (19‐94) isolated from human serum (Abcam; Cambridge, United Kingdom, Abcam.com),
Techniques: Fluorescence, Virus, Incubation, Comparison, Control
Journal: Journal of Leukocyte Biology
Article Title: Effects of serum amyloid protein A on influenza A virus replication and viral interactions with neutrophils
doi: 10.1002/JLB.4AB0220-116RR
Figure Lengend Snippet: Effect of SAA and or HDL on neutrophil IL‐8 production or caspase activity—In panel A, IL‐8 production by neutrophils was measured by ELISA as described in Section 2 (“Materials And Methods”). ** = P < 0.01 compared to control. Results represent mean ± sem for 3 to 5 experiments. Panel B shows IL‐8 production in response to influenza A virus (IAV) alone or IAV combined with Apo‐serum amyloid A (Apo‐SAA1). Panel C shows caspase 3 activation by IAV alone or IAV combined with Apo‐SAA1, SAAHDL (SAA complexed with HDL), SAA1, or HDL. * = P < 0.05 compared to results with neutrophils in media alone. Results are mean ± sem of 4 experiments
Article Snippet: We tested several commercially available forms of SAA1, including native human serum SAA complexed with HDL (SAAHDL; Fisher Scientific), SAA (19‐94) isolated from human serum (Abcam; Cambridge, United Kingdom, Abcam.com),
Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Control, Virus, Activation Assay
Journal: Journal of Leukocyte Biology
Article Title: Effects of serum amyloid protein A on influenza A virus replication and viral interactions with neutrophils
doi: 10.1002/JLB.4AB0220-116RR
Figure Lengend Snippet: Effects of TLR2 blocking antibodies, pertussis toxin (PT), and wortmannin of neutrophil responses to Apo‐serum amyloid A (Apo‐SAA1)
Article Snippet: We tested several commercially available forms of SAA1, including native human serum SAA complexed with HDL (SAAHDL; Fisher Scientific), SAA (19‐94) isolated from human serum (Abcam; Cambridge, United Kingdom, Abcam.com),
Techniques: Blocking Assay, Control, Virus
Journal: Cell metabolism
Article Title: Cytoarchitectural multi-depot profiling reveals immune-metabolic crosstalk in human colon-associated adipose tissue
doi: 10.1016/j.cmet.2025.12.008
Figure Lengend Snippet: (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of SAA1 mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.
Article Snippet:
Techniques: Comparison, Protein-Protein interactions, Expressing, Derivative Assay, Control, Enzyme-linked Immunosorbent Assay, Incubation, DNA Methylation Assay
Journal: Cell metabolism
Article Title: Cytoarchitectural multi-depot profiling reveals immune-metabolic crosstalk in human colon-associated adipose tissue
doi: 10.1016/j.cmet.2025.12.008
Figure Lengend Snippet: (A) Top Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways based on differentially expressed genes from comparisons of SAA1- or LPS-treated vs. control-treated adipose-derived stromal-vascular cells. (B) Network view of the six common SAA1- and LPS-regulated pathways showing shared and treatment-specific genes. (C) Expression scores for SAA1- (left) and LPS-responsive (right) genes following a 6-h incubation with either ligand in stromal-vascular cells from subcutaneous human WAT. Results are displayed on the uniform manifold approximation and projection panel from and violin plots for each indicated cell class. Note that adipocytes and mesothelial cells were removed as these are not present in the stromal-vascular fraction from the subcutaneous depot. (D) Representative immunostaining of epiploic adipose tissue using antibodies directed against markers for Adipo SAA (CES1) and macrophages (CD68). Hoechst33342 was used as the counterstain for nuclei. Scale bar, 100 μm. ASPC, adipose stromal and progenitor cell; NES, normalized enrichment score.
Article Snippet:
Techniques: Control, Derivative Assay, Expressing, Incubation, Immunostaining